Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
暂无分享,去创建一个
D. Siegel | J. H. Lee | R. Hájek | A. Oriol | J. Minařík | K. Song | V. Hungria | P. Rajnics | S. Aggarwal | M. Obreja